1
|
Iezzi R, Casà C, Posa A, Cornacchione P, Carchesio F, Boldrini L, Tanzilli A, Cerrito L, Fionda B, Longo V, Miele L, Lancellotta V, Cellini F, Tran HE, Ponziani FR, Giuliante F, Rapaccini GL, Grieco A, Pompili M, Gasbarrini A, Valentini V, Gambacorta MA, Tagliaferri L, Manfredi R. Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1). Eur Rev Med Pharmacol Sci 2022; 26:2891-2899. [PMID: 35503635 DOI: 10.26355/eurrev_202204_28620] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE The objective of this study is to find a contrast-enhanced CT-radiomic signature to predict clinical incomplete response in patients affected by hepatocellular carcinoma who underwent locoregional treatments. PATIENTS AND METHODS 190 patients affected by hepatocellular carcinoma treated using focal therapies (radiofrequency or microwave ablation) from September 2018 to October 2020 were retrospectively enrolled. Treatment response was evaluated on a per-target-nodule basis on the 6-months follow-up contrast-enhanced CT or MR imaging using the mRECIST criteria. Radiomics analysis was performed using an in-house developed open-source R library. Wilcoxon-Mann-Whitney test was applied for univariate analysis; features with a p-value lower than 0.05 were selected. Pearson correlation was applied to discard highly correlated features (cut-off=0.9). The remaining features were included in a logistic regression model and receiver operating characteristic curves; sensitivity, specificity, positive and negative predictive value were also computed. The model was validated performing 2000 bootstrap resampling. RESULTS 56 treated lesions from 42 patients were selected. Treatment responses were: complete response for 26 lesions (46.4%), 18 partial responses (32.1%), 10 stable diseases (17.9%), 2 progression diseases (3.6%). Area-Under-Curve value was 0.667 (95% CI: 0.527-0.806); accuracy, sensitivity, specificity, positive and negative predictive values were respectively 0.66, 0.85, 0.50, 0.59 and 0.79. CONCLUSIONS This contrast-enhanced CT-based model can be helpful to early identify poor responder's hepatocellular carcinoma patients and personalize treatments.
Collapse
Affiliation(s)
- R Iezzi
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia - U.O.C. Radiologia Diagnostica e Interventistica Generale, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Rigamonti C, Coco B, Brunetto M, Labanca S, Giannini E, Magro B, Fagiuoli S, Baroni GS, Sgamato C, Miele L, Grieco A, Giuli L, Manfredi G, Pirisi M. Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination. Dig Liver Dis 2022. [PMCID: PMC8935163 DOI: 10.1016/j.dld.2022.01.093] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- C. Rigamonti
- Department of Translational Medicine, Università del Piemonte Orientale and Division of Internal Medicine, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
| | - B. Coco
- Hepatology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - M. Brunetto
- Hepatology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - S. Labanca
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - E.G. Giannini
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - B. Magro
- Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - S. Fagiuoli
- Gastroenterology, Hepatology and Liver Transplantation, Department of Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - G. Svegliati Baroni
- SOSD Danno Epatico e Trapianti, Università Politecnica delle Marche, Ancona, Italy
| | - C. Sgamato
- Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples ``Federico II'', Naples, Italy
| | - L. Miele
- Unità di Medicina Interna e del Trapianto di Fegato, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del S. Cuore, Roma, Italy
| | - A. Grieco
- Unità di Medicina Interna e del Trapianto di Fegato, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del S. Cuore, Roma, Italy
| | - L. Giuli
- Unità di Medicina Interna e del Trapianto di Fegato, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del S. Cuore, Roma, Italy
| | - G.F. Manfredi
- Department of Translational Medicine, Università del Piemonte Orientale and Division of Internal Medicine, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
| | - M. Pirisi
- Department of Translational Medicine, Università del Piemonte Orientale and Division of Internal Medicine, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
| |
Collapse
|
3
|
Basile U, Miele L, Napodano C, Ciasca G, Gulli F, Pocino K, De Matthaeis N, Liguori A, De Magistris A, Marrone G, Biolato M, Marino M, Di Giacinto F, Gasbarrini A, Grieco A, Rapaccini GL. The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: a pilot study. Eur Rev Med Pharmacol Sci 2021; 24:12675-12685. [PMID: 33378014 DOI: 10.26355/eurrev_202012_24165] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Hepatocellular carcinoma (HCC) is a primary liver tumor derived from metabolic or viral chronic hepatitis, with few treatment options in advanced cases. New biomarkers that allow improving diagnosis and staging are widely desired. Here, we aim to evaluate the performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) in combination with α-fetoprotein (AFP), in the diagnosis of HCC in patients with metabolic or viral hepatitis. PATIENTS AND METHODS We enrolled 60 HCC patients (20 metabolic and 40 viral) and 20 healthy subjects (HS) as negative controls. PIVKA-II, AFP, Matrix metalloproteinase-9 (MMP-9) and Fibroblast growth factor (FGF) serum levels were assessed by immunoassays. RESULTS AFP and PIVKA-II levels were obviously higher in patients than in HS. AFP displayed a better diagnostic performance than PIVKA-II for viral HCC while PIVKA-II was better for metabolic HCC. The combination of the two biomarkers did not improve the discriminating ability. CONCLUSIONS PIVKA-II may be considered an independent predictor of macrovascular invasion from HCC cells and it can be used to better stratify HCC patients and should be evaluated in prospective studies for early detection of advanced HCC in metabolic subjects.
Collapse
Affiliation(s)
- U Basile
- Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Giraldi L, Miele L, Aleksovska K, Manca F, Leoncini E, Biolato M, Arzani D, Pirro MA, Marrone G, Cefalo C, Racco S, Liguori A, Rapaccini G, Miggiano GA, Gasbarrini A, Boccia S, Grieco A. Mediterranean diet and the prevention of non-alcoholic fatty liver disease: results from a case-control study. Eur Rev Med Pharmacol Sci 2021; 24:7391-7398. [PMID: 32706078 DOI: 10.26355/eurrev_202007_21907] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVE Few studies report that Mediterranean dietary (MD) pattern has a beneficial role in the progression of non-alcoholic fatty liver disease (NAFLD). Evidence on its potential effect on the onset of disease are, however, scanty. With our study, we evaluated whether MD affects the risk of NAFLD with a large case-control study performed in Italy. PATIENTS AND METHODS Three hundred and seventy-one cases of NAFLD and 444 controls were questioned on the demographic data and their dietary habits before diagnosis. Additionally, information about lifestyles and other related diseases, such as hypertension and diabetes mellitus were collected. The MD adherence was assessed using a pre-defined Mediterranean Diet Score (MDS). Odds ratios (OR) and 95% confidence intervals (CI) were obtained using a multiple logistic regression model. RESULTS A high adherence to the MD is significantly associated with decreased risk of NAFLD (OR: 0.83 95% CI: 0.71-0.98). When the different MD components were examined separately, higher legumes consumption (OR: 0.62 95% CI: 0.38-0.99) and high fish consumption (OR 0.38 95% CI: 0.17-0.85) were reported to be protective against NAFLD. CONCLUSIONS Our study shows that a high adherence to the MD decreases the risk of NAFLD.
Collapse
Affiliation(s)
- L Giraldi
- Department Of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Papa A, Covino M, Pizzolante F, Miele L, Lopetuso LR, Bove V, Iorio R, Simeoni B, Vetrone LM, Tricoli L, Mignini I, Schepis T, D'Alessandro A, Coppola G, Nicoletti T, Visconti E, Rapaccini G. Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19. Eur Rev Med Pharmacol Sci 2020; 24:7506-7511. [PMID: 32706091 DOI: 10.26355/eurrev_202007_21923] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVE The Coronavirus Disease 2019 (COVID-19) pandemic mainly involves respiratory symptoms, though gastrointestinal (GI) symptoms are increasingly being recognized. In this context, the presence of comorbidities appears to be associated with adverse outcomes. However, the role of digestive manifestations is not yet well defined. The primary aim of this study was to assess the prevalence of GI symptoms and digestive comorbidities in a cohort of patients with COVID-19 compared to controls. The secondary aim was to determine the association of GI-symptoms and digestive comorbidities with clinical outcomes. PATIENTS AND METHODS Inpatients with COVID-19 and controls with similar symptoms and/or radiological findings were enrolled. Symptoms at admission and throughout hospitalization were collected as they were comorbidities. The measured clinical outcomes were mortality, intensive care unit admission and cumulative endpoint. RESULTS A total of 105 patients were included: 34 with COVID-19 and 71 controls. At admission, the prevalence of GI symptoms among COVID-19 patients was 8.8%. During hospitalization, the frequency of GI symptoms was higher in patients with COVID-19 than in controls (p=0.004). Among patients with COVID-19, the mortality and a cumulative endpoint rates of those with GI symptoms were both lower than for those without GI symptoms (p=0.016 and p=0.000, respectively). Finally, we found digestive comorbidities to be associated with a milder course of COVID-19 (p=0.039 for cumulative endpoint). CONCLUSIONS Our results highlighted the non-negligible frequency of GI symptoms in patients with COVID-19, partly attributable to the therapies implemented. In addition, the presence of GI symptoms and digestive comorbidities is associated with better outcomes. Most likely, digestive comorbidities do not hinder the host's immune response against SARS-COV-2, and the occurrence of GI symptoms might be linked to a faster reduction of the viral load via the faecal route.
Collapse
Affiliation(s)
- A Papa
- Gastroenterology Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Marrone G, Biolato M, Mercurio G, Capobianchi MR, Garbuglia AR, Liguori A, Vassallo G, Gasbarrini A, Miele L, Grieco A. Acute HEV hepatitis: clinical and laboratory diagnosis. Eur Rev Med Pharmacol Sci 2020; 23:764-770. [PMID: 30720185 DOI: 10.26355/eurrev_201901_16891] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Hepatitis E Virus (HEV) is probably the most common cause of acute hepatitis worldwide. It has been regarded for a long time as a disease limited to developing countries. Recently, the refinement of diagnostic techniques, on the one hand, and migratory flows, on the other hand, have also led to the identification of an increased number of HEV infections in industrialized countries. Four HEV genotypes have been identified across the world, with different epidemiological burdens and a wide range of clinical presentations. Here, we report a case series of acute HEV hepatitis observed in the last three years in our hospital. PATIENTS AND METHODS We performed a search for HEV IgM and IgG in all subjects admitted for acute hepatitis without evidence of other possible infectious, toxic or metabolic causes of liver damage. In subjects with HEV IgM positivity, the search for HEV-RNA was performed. RESULTS We diagnosed eight acute HEV infections: 2 epidemic and 6 sporadic forms. HEV-RNA was detected in serum in 2 cases. CONCLUSIONS HEV infection appears to be a cause of acute hepatitis that we must keep in mind even in developed countries.
Collapse
Affiliation(s)
- G Marrone
- Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Schepis T, Larghi A, Papa A, Miele L, Panzuto F, De Biase L, Annibale B, Cattani P, Rapaccini GL. SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. Pancreatology 2020; 20:1011-1012. [PMID: 32498972 PMCID: PMC7254005 DOI: 10.1016/j.pan.2020.05.016] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 05/13/2020] [Accepted: 05/23/2020] [Indexed: 02/05/2023]
Abstract
The involvement of gastrointestinal system in SARS-CoV2 related disease, COVID-19, is increasingly recognized. COVID-19 associated pancreatic injury has been suggested, but its correlation with pancreatic disease is still unclear. In this case report, we describe the detection of SARS-CoV2 RNA in a pancreatic pseudocyst fluid sample collected from a patient with SARS-CoV2 associated pneumonia and a pancreatic pseudocyst developed as a complication of an acute edematous pancreatitis. The detection of SARS-CoV2 within the pancreatic collection arise the question of whether this virus has a tropism for pancreatic tissue and whether it plays a role in pancreatic diseases occurrence.
Collapse
Affiliation(s)
- T Schepis
- Department of Medical and Surgical Sciences, Gastroenterology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.
| | - A Larghi
- Department of Medical and Surgical Sciences, Gastroenterology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
| | - A Papa
- Department of Medical and Surgical Sciences, Gastroenterology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
| | - L Miele
- Department of Medical and Surgical Sciences, Gastroenterology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
| | - F Panzuto
- Department of Clinical Sciences and Tralational Medicine, Digestive Disease Unit, Sant'Andrea University Hospital, Rome, Italy
| | - L De Biase
- Department of Clinical and Molecular Medicine, Heart Failure Unit, Sant'Andrea University Hospital, Rome, Italy
| | - B Annibale
- Department of Clinical Sciences and Tralational Medicine, Digestive Disease Unit, Sant'Andrea University Hospital, Rome, Italy
| | - P Cattani
- Department of Laboratory and Infective Sciences, Virology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
| | - G L Rapaccini
- Department of Medical and Surgical Sciences, Gastroenterology Unit, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy
| |
Collapse
|
8
|
Fanin A, Miele L, Bertolini E, Giorgini A, Pontiroli AE, Benetti A. Liver alterations in anorexia nervosa are not caused by insulin resistance. Intern Emerg Med 2020; 15:337-339. [PMID: 31734856 DOI: 10.1007/s11739-019-02227-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 10/25/2019] [Indexed: 12/30/2022]
Abstract
BACKGROUND Liver dysfunction has been widely reported in connection with anorexia nervosa (AN) but the pathogenesis of these alterations has never been fully understood despite reported theories about the presence of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). The aim of this study is to investigate if hypertransaminasemia in AN is linked to IR and NAFLD. METHODS Anthropometric data and laboratory exams of 34 patients and 34 controls were analyzed, including alanine-aminotransferase, aspartate-aminotransferase and homeostatic model assessment of insulin resistance (HOMA-IR) index. All subjects also underwent magnetic resonance imaging (MRI), ultrasonography (US), and transient elastography (TE). RESULTS Evidence of increased alanine aminotransferase in AN patients was confirmed in our sample together with a lower HOMA-IR index compared to controls. Positive results in US appeared in 16 patients vs none in controls (p = 0.0007); patients with liver parenchyma abnormalities in US were not different than normal-US patients in any of the studied variables. Only one patient showed non-alcoholic fatty liver disease in MRI while abnormal TE was found in four patients and never in controls. CONCLUSIONS Liver damage suggested by increased serum liver enzymes cannot be due to liver steatosis but potentially to a different liver disease (not identified by MRI) or to an early liver fibrosis not associated with an insulin-resistant status.
Collapse
Affiliation(s)
- Alice Fanin
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy.
| | - Lucia Miele
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy
| | - Emanuela Bertolini
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy
| | - Alessia Giorgini
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy
| | - Antonio Ettore Pontiroli
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy
| | - Alberto Benetti
- Dipartimento di Scienze della Salute, Ospedale San Paolo, Università degli Studi di Milano, via A. Di Rudinì 8, Milan, Italy
| |
Collapse
|
9
|
Gulli F, Basile U, Gragnani L, Napodano C, Pocino K, Miele L, Santini SA, Zignego AL, Gasbarrini A, Rapaccini GL. IgG cryoglobulinemia. Eur Rev Med Pharmacol Sci 2019; 22:6057-6062. [PMID: 30280791 DOI: 10.26355/eurrev_201809_15943] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Mixed Cryoglobulinemia is the most well-known Hepatitis C Virus (HCV)-associated extrahepatic manifestation. MC is both an autoimmune and B-lymphoproliferative disorder. Cryoglobulins (CGs) are classified into three groups according to immunoglobulin (Ig) composition: type I is composed of one isotype or Ig class. Type II and type III mixed CGs are immune complexes composed of polyclonal IgGs acting as autoantigens and mono, polyclonal or oligoclonal IgM with rheumatoid factor activity. IgG1 and IgG3 are the predominant subclasses involved. This study shows the simultaneous presence of IgG-RF and IgG3, supporting the hypothesis of an involvement of this subclass in the initiation of early stages of CGs. PATIENTS AND METHODS We describe a case series of six HCV-positive patients, all of whom had peripheral neuropathy and transient ischemic attacks, presenting cryoprecipitates formed by IgG3 and IgG1. Cryoprecipitate IgG subclass research was carried out by immunofixation electrophoresis by using antisera against IgG1, IgG2, IgG3, and IgG4. RESULTS Our six patients presented with an immunochemical pattern characterized by the mere presence of IgG1 and IgG3 subclasses with probable RF activity and one of these six patients exhibited monoclonal IgG3 in his cerebrospinal fluid. CONCLUSIONS We can hypothesize that the IgG passage through the blood-brain barrier could have contributed to the cause of TIAs, through a mechanism involving the precipitation of circulating immune complexes formed by the two subclasses in the intrathecal vessels.
Collapse
Affiliation(s)
- F Gulli
- Clinical Pathology Laboratory, Ospedale Madre Giuseppina Vannini, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Majumder S, Crabtree J, Hossain F, Murone M, Lehal R, Miele L. Abstract P4-07-05: A novel, first in class Notch transcriptional inhibitor, CB-103 has activity on luminal breast cancer stem cells in combination with fulvestrant. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Notch signaling pathway plays a central role in cellular differentiation, growth and stem cell maintenance. Expression and activation of Notch pathway receptors and ligands have differential outcomes depending on the tissue, localization and cell type. When Notch pathway is aberrantly activated by genetic lesions, it can be a major driver for Notch-dependent cancers and can cause resistance to standard of care treatment. We and others have shown that in Estrogen Receptor (ER)-positive breast cancers, estrogen deprivation caused by endocrine therapy results in Notch1 and Notch4 activation. In turn, Notch1 stimulated ER-dependent transcription in the absence of estrogen, causing endocrine resistance. Combinations of Notch inhibitors and endocrine therapy are effective in preclinical models of ER-positive breast cancer and have shown promising signals in early clinical trials.
Cellestia's lead development candidate CB-103 is a small molecule, first-in-class, oral pan-Notch inhibitor. CB-103 selectively blocks Notch pathway activation-related gene transcription through binding to a Notch specific protein in the transcription factor complex. The blockade occurs by protein-protein interaction inhibition with a binding site critical for the assembly of the Notch transcription complex. This is a unique mode of action, which allows blocking Notch signaling regardless of the genetic lesions which have activated the pathway.
We have performed mammosphere assays to test the potency and efficacy of this compound on stem cell ability to form sphere. We used two different doses of CB-103; either alone or in combination with a fixed dose of Fulvestrant (30nM), a SERD, in our mammosphere assays. Two different ER+ luminal,endocrine resistant cell lines were tested and compared with their parental controls. From our data, it's apparent that there is a synergistic effect when using CB-103 in combination with Fulvestrant. It's also evident that the efficacy of CB-103 is maximal maximizes at the lowest concentration tested in our assays. The combination was effective in 3 out of 4 models. However, the effect of CB-103 on MCF7-TAMR either as a single agent or in combination was not statistically significant.
Cellestia has received regulatory approval to start clinical development with CB-103 in a first-in-human study Phase l – lla study investigating safety (Ph l) and preliminary single agent efficacy (Ph lla) of CB-103 in patients with advanced solid cancers and haematological malignancies. Our data support the notion of testing this agent in ER-positive breast cancer in combination with SERDs.
Citation Format: Majumder S, Crabtree J, Hossain F, Murone M, Lehal R, Miele L. A novel, first in class Notch transcriptional inhibitor, CB-103 has activity on luminal breast cancer stem cells in combination with fulvestrant [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-07-05.
Collapse
Affiliation(s)
- S Majumder
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| | - J Crabtree
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| | - F Hossain
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| | - M Murone
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| | - R Lehal
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| | - L Miele
- LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland
| |
Collapse
|
11
|
Ucar DA, Matossian MD, Hoang-Barnes VT, Hossain FM, Gupta M, Burks HE, Wright TD, Cavanaugh J, Flaherty P, Burow ME, Miele L. Abstract P2-03-04: A novel druggable target upstream of Notch: MEK5/ERK5 signaling regulates Jagged-1 and Notch1 expression in triple negative breast cancer stem cells. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-03-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) is a molecularly heterogeneous, clinically aggressive disease group that is highly prevalent among African-Americans and younger patients. Standard chemo/radio therapy often produces clinical responses, but recurrence and metastasis are unfortunately common. Metastatic disease is generally incurable. Chemo/radiotherapy has been shown to induce EMT and enrich a chemo-resistant cancer stem-like cell (CSC) population in TNBC. CSCs are thought to drive disease recurrence. Notch signaling is critical for maintenance of TNBC CSC. Expression of Notch1 and its ligand Jagged1 are correlated with poor prognosis. Efforts to pharmacologically target Notch with Gamma Secretase Inhibitors (GSIs) have been impaired by the systemic toxicity of the GSIs, and by the fact that Notch1 also plays a key role in anti-tumor adaptive immunity. Therapeutic agents that indirectly and selectively target Notch signaling in breast cancer cells would be a potentially attractive strategy. However, no such agents have been identified to date. We have found that the MAPK5-ERK5 kinase pathway, which contains at least two druggable targets, functions as a master regulator of Notch signaling in TNBC cells. ERK5 knockout TNBC cells have dramatically decreased expression of Notch receptors, ligands and transcriptional targets. In vivo, these cells form barely detectable tumors that do not metastasize and express lower levels of Notch1 and its ligand Jagged1. Using in silico screening, we identified a class of compounds that selectively target MAP2K5 (MEK5) and decrease the phosphorylation of MAPK7 (ERK5). We selected compound SC-181 for further study. Consistent with ERK5KO cells, pharmacological suppression of ERK5 phosphorylation with SC-181 decreased Notch1 and Jagged1 mRNAs and proteins. SC-181 reversed EMT and reduced the CD44hi/CD24lo CSC population in TNBC cells, but had no effect on T-cell proliferation. SC-181 decreased the number and size of mammospheres in a concentration-dependent manner. Overexpression of the Notch1 intracellular domain (N1IC) in ERK5KO cells rescues their phenotype, dramatically increasing the CSC fraction and promoting EMT. Our results suggest that targeting the MEK5-ERK5 pathway is a promising new strategy to selectively modulate Notch signaling in TNBC CSC without compromising tumor immunity.
Citation Format: Ucar DA, Matossian MD, Hoang-Barnes VT, Hossain FM, Gupta M, Burks HE, Wright TD, Cavanaugh J, Flaherty P, Burow ME, Miele L. A novel druggable target upstream of Notch: MEK5/ERK5 signaling regulates Jagged-1 and Notch1 expression in triple negative breast cancer stem cells [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-03-04.
Collapse
Affiliation(s)
- DA Ucar
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - MD Matossian
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - VT Hoang-Barnes
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - FM Hossain
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - M Gupta
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - HE Burks
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - TD Wright
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - J Cavanaugh
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - P Flaherty
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - ME Burow
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| | - L Miele
- LCRC, New Orleans, LA; Tulane Medical School, New Orleans, LA; Duquesne University, Pittsburgh, PA; NIH, Frederick, MD
| |
Collapse
|
12
|
Hossain F, Ucar D, Majumder S, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Abstract P6-22-01: Repurposing sulindac sulfide as a notch inhibitor to target cancer stem-like cells in triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-22-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous group of clinically aggressive breast cancers. TNBC patients have a high risk of recurrence and metastasis, and current treatment options remain limited. There is strong evidence supporting the involvement of Notch signaling in TNBC progression. Expression of Notch1 and its ligand Jagged1 correlate with poor prognosis. Emerging evidence suggests that cancer stem-like cells (CSCs) that escape chemo or radiation therapy in TNBC are often Notch-dependent. At the same time, there is evidence that active tumor immunity predicts good response to neo-adjuvant chemotherapy in TNBC. Notch inhibitors, including Gamma Secretase Inhibitors (GSIs) are quite effective in preclinical models of TNBC, where they eliminate CSCs resistant to chemotherapy. However, the success of GSIs in clinical trials is limited by their intestinal toxicity and adverse immunological effects. CD4 and CD8 T-cells, necessary to adaptive tumor immunity, require Notch1 for activation. Our overarching goal is to replace GSIs with agents that lack their systemic toxicity and adverse immunological effects. We identified Sulindac Sulfide (SS), the active metabolite of FDA-approved NSAID Sulindac, as a potential candidate to replace GSI. SS has Gamma Secretase Modifier (GSM) activity. We confirmed that SS inhibits Notch1 cleavage in TNBC cells. SS significantly inhibited mammosphere growth in all human and murine TNBC models we tested: 1) human MDA-MB-231 cells; 2) murine TNBC model C0321, from targeted conditional knockout of Lunatic Fringe (LFng-/-); and 3) Two TNBC patient-derived xenograft models, 2K1 and 4IC. In contrast, SS did not inhibit Notch expression or cleavage in murine T cells. In C0321 tumors, which recapitulate human mesenchymal TNBC, we found that SS had remarkable single-agent anti-tumor activity and virtually eliminated Notch1 expression in tumors. SS caused an increase in intra-tumoral CD11c+ dendritic cells, but decreased CD4 cells, which in this model are largely PD-1 positive (exhausted). CD8 cells were modestly increased. SS did not affect the number of tumor infiltrating macrophages or myeloid-derived suppressor cells (MDSC). However, SS blocked the immunosuppressive function of bone marrow-derived MDSC. We are currently investigating the mechanisms of this anti-tumor activity. Our data support further investigation of SS for the treatment of TNBC, with standard of care or with immunotherapy agents. Repurposing an FDA-approved, safe agent for the treatment of TNBC would be significantly easier and more cost-effective than developing unproven investigational agents.
Citation Format: Hossain F, Ucar D, Majumder S, Xu K, Ran Y, Minter L, Xi Y, Burow M, Golde T, Osborne B, Miele L. Repurposing sulindac sulfide as a notch inhibitor to target cancer stem-like cells in triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-22-01.
Collapse
Affiliation(s)
- F Hossain
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - D Ucar
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - S Majumder
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - K Xu
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - Y Ran
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - L Minter
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - Y Xi
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - M Burow
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - T Golde
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - B Osborne
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| | - L Miele
- LSUHSC, New Orleans, LA; University of Mississippi, Jackson, MS; University of Florida, Gainesville, FL; University of Massachusetts Amherst, Amherst, MA; Tulane University, New Orleans, LA
| |
Collapse
|
13
|
Prussick R, Miele L. 银屑病患者中的非酒精性脂肪肝. Br J Dermatol 2018. [DOI: 10.1111/bjd.16877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Prussick R, Miele L. Nonalcoholic fatty liver disease in psoriasis. Br J Dermatol 2018. [DOI: 10.1111/bjd.16863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 2018; 179:16-29. [PMID: 29235656 DOI: 10.1111/bjd.16239] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/06/2017] [Indexed: 02/06/2023]
Abstract
Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor-α and interleukin-6) and hepatokines, and decreased levels of adiponectin, an anti-inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.
Collapse
Affiliation(s)
- R B Prussick
- Washington Dermatology Center, Rockville, MD, U.S.A.,Department of Dermatology, George Washington University, Washington, DC, U.S.A
| | - L Miele
- Institute of Internal Medicine, Catholic University of Sacred Heart of Rome, Rome, Italy.,Gastroenterological Area, Gastroenterology and Endocrine-Metabolic Sciences Department, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| |
Collapse
|
16
|
Duarte SMB, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada LSRR, de Barros Costa FG, Toda K, Mazo DFC, Sabino EC, Carrilho FJ, Gasbarrini A, Oliveira CP. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis 2018; 28:369-384. [PMID: 29482963 DOI: 10.1016/j.numecd.2017.10.014] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 10/09/2017] [Accepted: 10/13/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND AIM The aim of the study was to compare the gut microbiomes from obese and lean patients with or without NASH to outline phenotypic differences. METHODS AND RESULTS We performed a cross-sectional pilot study comprising biopsy-proven NASH patients grouped according to BMI. Microbiome DNA was extracted from stool samples, and PCR amplification was performed using primers for the V4 region of the 16S rRNA gene. The amplicons were sequenced using the Ion PGM Torrent platform, and data were analyzed using QIIME software. Macronutrient consumption was analyzed by a 7-day food record. Liver fibrosis ≥ F2 was associated with increased abundance of Lactobacilli (p = 0.0007). NASH patients showed differences in Faecalibacterium, Ruminococcus, Lactobacillus and Bifidobacterium abundance compared with the control group. Lean NASH patients had a 3-fold lower abundance of Faecalibacterium and Ruminococcus (p = 0.004), obese NASH patients were enriched in Lactobacilli (p = 0.002), and overweight NASH patients had reduced Bifidobacterium (p = 0.018). Moreover, lean NASH patients showed a deficiency in Lactobacillus compared with overweight and obese NASH patients. This group also appeared similar to the control group with regard to gut microbiome alpha diversity. Although there were qualitative differences between lean NASH and overweight/obese NASH, they were not statistically significant (p = 0.618). The study limitations included a small sample size, a food questionnaire that collected only qualitative and semi-quantitative data, and variations in group gender composition that may influence differences in FXR signaling, bile acids metabolism and the composition of gut microbiota. CONCLUSION Our preliminary finding of a different pathogenetic process in lean NASH patients needs to be confirmed by larger studies, including those with patient populations stratified by sex and dietary habits.
Collapse
Affiliation(s)
- S M B Duarte
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - J T Stefano
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - L Miele
- Division of Internal Medicine, Gastroenterology and Hepatology, Area Gastroenterologica, Fondazione Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore, Rome, Italy.
| | - F R Ponziani
- Division of Internal Medicine, Gastroenterology and Hepatology, Area Gastroenterologica, Fondazione Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Souza-Basqueira
- Departamento de Doenças Infecciosas e Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - L S R R Okada
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - F G de Barros Costa
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - K Toda
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - D F C Mazo
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - E C Sabino
- Departamento de Doenças Infecciosas e Instituto de Medicina Tropical, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - F J Carrilho
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
| | - A Gasbarrini
- Division of Internal Medicine, Gastroenterology and Hepatology, Area Gastroenterologica, Fondazione Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore, Rome, Italy
| | - C P Oliveira
- Divisao de Gastroenterologia e Hepatologia, Departamento de Gastroenterologia (LIM-07), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
| |
Collapse
|
17
|
Hossain F, Sorrentino C, Ucar Bilyeu AD, Matossian M, Crabtree J, Pannuti A, Burow M, Golde T, Osborne B, Miele L. Abstract P6-07-06: Targeting cancer stem-like cells metabolism via non-canonical notch signaling pathways in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous group of clinically aggressive diseases. TNBC patients have high risk of recurrence and metastasis, and current treatment options remain limited. Cancer stem-like cells (CSCs) have been linked to cancer initiation, progression and chemotherapy resistance. Therefore CSC-targeted therapies are keenly sought. There is strong evidence for the involvement of Notch signaling in TNBC. Notch1 is highly expressed in Basal-like 1 (BL1) and especially Mesenchymal-Stem-Like (MSL) TNBCs. Expression of Notch1 and its ligand Jagged1 correlate with poor prognosis. Moreover, strong evidence supports key roles of different Notch paralogs in breast CSCs. Here, we demonstrate that Notch activation by Jagged1-expressing stromal cells enhances transcription of the anti-apoptotic gene cIAP-2 (BIRC3), a known NF-κB target. This event is dependent on recruitment to the cIAP-2 promoter of NF-κB subunits, IKKα and Notch1. Short term exposure of MDA-MB-231 cells (MSL, PTEN wild-type), but not MDA-MB-468 cells (BL1, PTEN-null) to recombinant Jagged1 leads to AKT phosphorylation. This is suppressed by AKT inhibitors, IKK inhibitors, and dual mTORC1/2 inhibitors but not an mTORC1-selective inhibitor. These observations support a model where canonical and non-canonical mechanisms downstream of Notch1 trigger AKT phosphorylation and NF-κB activation in PTEN wild type TNBC cells. Rapid AKT phosphorylation downstream of Notch1 requires mTORC2, PI3K and IKKα, and contributes to NF-κB activation. This suggests a bidirectional crosstalk between the IKKα and AKT arms of this Jagged1-activated pathway. Importantly, we find co-localization of Notch1 with Mitochondria in MDA-MB-231 cells by confocal microscopy and Western blot of isolated mitochondrial fractions. We demonstrate that recombinant Jagged1 increases metabolism of TNBC cells. Knockdown of Notch1 or IKKα by siRNA decreases mitochondrial respiration and glycolysis. CSCs derived from MDA-MB-231 cells have increased Notch1, p-AKT, and oxidative metabolism compared to non-stem cells. AKT inhibition or IKK inhibition decreases both mitochondrial respiration and glycolysis of TNBC derived CSCs. Pharmacological inhibition of Notch cleavage by gamma secretase inhibitor (PF-03084014) in combination with AKT inhibitor (MK-2206) or IKK inhibitor (Bay11-7082) blocks CD90hi or CD44+CD24low sorted secondary mammospheres formation. Notably, we find similar results in TNBC patient derived xenograft (PDX) models. These data suggest that combination treatments affecting the intersection of Notch, NF-kB and AKT pathways have potential therapeutic importance in targeting CSCs in TNBC cases with high Notch1 expression.
Citation Format: Hossain F, Sorrentino C, Ucar Bilyeu AD, Matossian M, Crabtree J, Pannuti A, Burow M, Golde T, Osborne B, Miele L. Targeting cancer stem-like cells metabolism via non-canonical notch signaling pathways in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-07-06.
Collapse
Affiliation(s)
- F Hossain
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - C Sorrentino
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - AD Ucar Bilyeu
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - M Matossian
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - J Crabtree
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - A Pannuti
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - M Burow
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - T Golde
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - B Osborne
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| | - L Miele
- LSUHSC, New Orleans, LA; University of Florida, Gainesville, FL; Tulane University, New Orleans, LA; University of Massachusetts Amherst, Amherst, MA
| |
Collapse
|
18
|
Miele L, Liguori A, Marrone G, Biolato M, Araneo C, Vaccaro FG, Gasbarrini A, Grieco A. Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci 2017; 21:86-94. [PMID: 28379591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Drug-induced liver injury (DILI) is a common and underestimated cause of liver disease. Several drugs and other xenobiotics can be the cause of different clinicopathologic patterns of liver disease. Steatosis and steatohepatitis are rare but well-documented types of DILI. Over the past decades commonly used drugs like amiodarone, tamoxifen, irinotecan, methotrexate, valproic acid and glucocorticoids have been recognized to be associated with steatosis. Even though the pathophysiological pathways are still only partially understood, inhibition of mitochondrial beta-oxidation, reduced very low-density lipoprotein secretion, insulin resistance induction and increased de novo synthesis or increased liver uptake of fatty acids are considered the main pathogenic mechanisms through which drugs can lead to hepatic steatosis. On the other hand, fatty liver itself is a very common clinical condition, and there is a growing awareness of the potential risk factors for DILI due to the underlying metabolic condition itself.
Collapse
Affiliation(s)
- L Miele
- Institute of Internal Medicine and Gastroenterology Area, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Marrone G, Vaccaro FG, Biolato M, Miele L, Liguori A, Araneo C, Ponziani FR, Mores N, Gasbarrini A, Grieco A. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci 2017; 21:122-134. [PMID: 28379587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
A drug-induced liver injury (DILI) is defined as a liver injury caused by exposure to a drug or a non-infectious toxic agent with a variable degree of organ dysfunction. A better understanding of DILI epidemiology has been obtained in recent years with the institution of international registries in the United States and Europe. Despite the advances in the understanding and characterization of the phenomenon, DILI remains an exclusion diagnosis so, probability scores and the analysis of literature reports are useful tools in dealing with a suspected DILI. Idiosyncratic DILI can be considered a relatively rare event but it is one of the leading causes of acute liver failure. Thus, proper management is essential to avoid serious consequences. Here, we present an updated review of diagnostic and classification criteria of DILI. Prognostic tools, and principles of management and therapy have also been briefly discussed.
Collapse
Affiliation(s)
- G Marrone
- Gastroenterology Area, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Biolato M, Araneo C, Marrone G, Liguori A, Miele L, Ponziani FR, Gasbarrini A, Grieco A. Liver transplantation for drug-induced acute liver failure. Eur Rev Med Pharmacol Sci 2017; 21:37-45. [PMID: 28379596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVES To summarize the different clinical features of drug-induced acute liver failure, the diagnostic work-up, conservative management and the prognostic scores currently used to list patients for liver transplantation. EVIDENCE AND INFORMATION SOURCES The current review is based on an analysis of the current literature and the caseload experience of the Authors on this topic. STATE OF THE ART Drug-induced liver injury is the leading cause of acute liver failure in the adult population in Western countries, with a transplant-free survival rate of less than 50%. Main subtypes include paracetamol and idiosyncratic drug-induced injury, which differ in epidemiology, clinical course, prognosis and conservative management. In cases of a high likelihood of death, urgent hepatic transplantation is indicated, but the decision whether and when to put a patient with drug-induced acute liver failure on the list for urgent liver transplant is extremely difficult and requires constant interdisciplinary exchange and continuous updating of the clinical picture. CONCLUSIONS Intensive management should be done in a clinical tertiary referral center which has a specialized team of hepatologists and a liver transplant center.
Collapse
Affiliation(s)
- M Biolato
- Liver Transplant Medicine, Gastroenterological Area, Gastroenterological and Endocrino-Metabolic Sciences Department, Fondazione Policlinico Universitario Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Hossain F, Peng Y, Pannuti A, Backus K, Golde T, Osborne B, Miele L. Abstract P5-07-06: A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-07-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous group of clinically aggressive breast cancers. TNBC patients have high risk of recurrence and metastasis, and current treatment options remain limited. There is strong evidence for the involvement of Notch signaling in TNBC and in breast cancer stem-like cells (CSCs). Notch1 is highly expressed in Basal-like 1 (BL1) and especially Mesenchymal-Stem-Like (MSL) TNBCs. Expression of Notch1 and its ligand Jagged1 correlate with poor prognosis. Treatment of TNBC with dual mTORC1/2 inhibitors leads to resistance through activation of Notch1. Expression of Notch1 protein correlates with pAKT and nuclear NF-κB in TNBC. Here, we demonstrate that Notch1 promotes cell survival in MDA-MB-231 cells, representative of MSL TNBC, in part by activating NF-κB. Notch activation by Jagged1-expressing stromal cells enhances transcription of the anti-apoptotic gene cIAP-2 (BIRC3), a known NF-κB target. This event is dependent on recruitment to the cIAP-2 promoter of NF-κB subunits, IKKα and Notch1. Short term exposure of MDA-MB-231 cells (MSL, PTEN wild-type), but not MDA-MB-468 cells (BL1, PTEN-null) to recombinant Jagged1 leads to rapid AKT phosphorylation. This is suppressed by dual mTORC1/2 inhibitors, AKT inhibitors and IKKα inhibitors but not Everolimus (mTORC1-selective inhibitor). Rapid AKT phosphorylation downstream of Notch1 requires mTORC2, PI3K and IKKα, and contributes to NF-κB activation. These observations support a model where canonical and non-canonical mechanisms downstream of Notch1 trigger rapid AKT phosphorylation and NF-κB activation in PTEN wild-type TNBC cells. Both arms of this pathway require IKKα. CSCs derived from MDA-MB-231 cells have increased Notch1, pAKT and pIKKα expression. Combined pharmacological inhibition of Notch and AKT or Notch and IKKα completely blocks secondary mammosphere formation. These data and published literature suggest that: 1) IKKα connects the Notch and mTORC2/AKT pathways in some TNBC subtypes; 2) IKKα is also required for nuclear Notch1-mediated NF-kB activation and may be a critical node in the Notch signaling network; 3) A feedback mechanism may exist in some TNBC cells between mTORC2/AKT and Notch1; 4) The non-canonical Notch-IKKα-AKT pathway has a potential therapeutic role in targeting CSCs of selected TNBC subtypes.
Citation Format: Hossain F, Peng Y, Pannuti A, Backus K, Golde T, Osborne B, Miele L. A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-07-06.
Collapse
Affiliation(s)
- F Hossain
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - Y Peng
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - A Pannuti
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - K Backus
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - T Golde
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - B Osborne
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| | - L Miele
- LSUHSC, New Orleans, LA; Loyola University Chicago; University of Mississippi; University of Florida; University of Massachusetts Amherst
| |
Collapse
|
22
|
Wang G, Liu J, Zheng S, Miele L, Wiese T, Zhong Q, Guo S. Abstract P2-08-11: An orally bioavailable selective estrogen receptor downregulator. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Orally bioavailable selective estrogen receptor downregulators (SERDs) may offer greater systemic drug exposure, improved clinical efficacy, and more durable treatment outcome for breast cancer patients with disease progression following antiestrogen or aromatase inhibitor therapy. We report the design and synthesis of ZB716, a C-3 position boronic acid modified fulvestrant, which behaves as a steroidal SERD suitable for oral administration. ZB716 binds to ERa competitively at an IC50 of 4.1 nM as compared to 3.9 nM for fulvestrant, and it effectively downregulates ERa (IC50=12.7 nM) in both tamoxifen-sensitive (T47D) and tamoxifen-resistant (T47D/PKCa) breast cancer cells. It acts as an antiestrogen that exerts potent antiproliferative effects on tamoxifen-resistant breast cancer cells (MCF-7/TamR, T47D/PKCa, and T47D/Y537S). When orally administered to mice, rats, and Beagle dogs, ZB716 demonstrates superior oral bioavailability in all animal-based pharmacokinetic studies when compared to fulvestrant administered by subcutaneous injection. More importantly, orally administered ZB716 was found to potently inhibit xenograft tumor growth in mice. These pre-clinical data strongly suggest that ZB716 is a promising SERD drug that could offer significant improvement over existing SERD regimen of Faslodex. ZB716 is being prepared in an IND application for phase 1 clinical trial in ER+, HER2- advanced breast cancer patients.
Citation Format: Wang G, Liu J, Zheng S, Miele L, Wiese T, Zhong Q, Guo S. An orally bioavailable selective estrogen receptor downregulator [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-08-11.
Collapse
Affiliation(s)
- G Wang
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - J Liu
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - S Zheng
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - L Miele
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - T Wiese
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - Q Zhong
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| | - S Guo
- Xavier University of Louisiana, New Orleans, LA; LSU Health Sciences Center, New Orleans, LA
| |
Collapse
|
23
|
Patriarca G, Pogna N, Cammarota G, Schiavino D, Lombardo C, Pollastrini E, De Pasquale T, Buonomo A, Nocente F, Gazza L, Pietrini D, Miele L, Nucera E, Gasbarrini G. An Attempt of Specific Desensitising Treatment with Gliadin in Celiac Disease. Int J Immunopathol Pharmacol 2016; 18:709-14. [PMID: 16388719 DOI: 10.1177/039463200501800413] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Gluten-free diet is the current treatment of celiac disease. We decided to verify the occurrence of histological and serological modification and/or clinical manifestations during a gradual and progressive introduction of gliadin in the diet and if it may induce a tolerance to food, as it occurs in allergic patients. We studied the case of a celiac woman with complete clinical and histological remittance after 10 years of gluten free diet. She took increasing daily doses of gliadin, reaching the final dose of 9 g of gliadin (15 g of gluten) in 6 months. Then she started a free dietary regimen. During the 15-month follow-up period esophago-gastro-duodenoscopy showed normal Kerckring folds and villi. Anti-gliadin, anti-endomysium and anti-tissue-transglutaminase antibodies, as well as the haematological and biochemical parameters remained normal. Our results represent a new approach in the research concerning celiac disease, and could provide a future line of study for its management.
Collapse
Affiliation(s)
- G Patriarca
- Allergology Department, Catholic University Policlinico Gemelli, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Cianci R, Pinti M, Nasi M, Starnino S, Cammarota G, Miele L, De Luca A, Cauda R, Raducci F, Grieco A, Rapaccini G, Gasbarrini G, Cossarizza A, Pandolfi F. Impairment of Recent Thymic Emigrants in HCV Infection. Int J Immunopathol Pharmacol 2016; 18:723-8. [PMID: 16388721 DOI: 10.1177/039463200501800415] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Hepatitis C Virus (HCV) often has a more favorable course in younger patients. Considering the involution of the thymic function with age, we investigated the output of recent thymic emigrants (RTE) in HCV patients. To evaluate RTE, we used a competitive quantitative PCR in order to determine the percentages of cells with cj-T cell receptor excision circles (TREC). This study was performed in 14 HCV patients at diagnosis and before any anti-HCV treatment. The results obtained in this group were compared to those obtained in a group of age-matched controls. We found that in the 14 HCV patients naive for anti-HCV treatment the mean percentage of cj-TREC was 3%. We could not detect a correlation between the percentages of cj-TREC and age or patients' viremia. In contrast, in the 26 age-matched controls mean percentage of cj-TREC was 5.6% (P=0.01). Our study describes a novel immune defect in HCV patients. Additional studies are needed to get further insight in the possible role of TREC defect in the pathogenesis and prognosis of the disease.
Collapse
Affiliation(s)
- R Cianci
- Institute of Internal Medicine, Catholic University of Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Serrano-Gomez SJ, Sanabria MC, Hernández-Suarez GA, Garcia O, Silva C, Romero A, Mejía JC, Fejerman L, Antonia T, Miele L, Zabaleta J. Abstract P1-08-09: Increased prevalence of luminal B subtype in Colombian women with breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-08-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is the most frequent malignancy in women worldwide. Distinct intrinsic subtypes of breast cancer have different prognoses, and their relative prevalence varies significantly among ethnic groups. Hispanic/Latino (H/L) populations are a genetically admixed and heterogeneous group, with variable levels of European, Native American and African ancestries. Breast cancer in H/L patients is understudied from a molecular standpoint, and most studies reported so far include limited numbers of H/L patients and assign ethnicity based on self-reported data rather than ancestry. This is the first study to explore the prevalence of breast cancer intrinsic subtypes in Colombia and their association with clinicopathological data and genetic ancestry.
Methods: Immunohistochemistry surrogates from the 2013 St. Gallen International Expert Consensus were applied to classify breast cancer into intrinsic subtypes in 301 patients diagnosed between 2008 and 2012 at the Colombian National Cancer Institute. We analyzed the distribution of subtypes by age, histologic type, node status, margins at surgery, AJCC stage, tumor size, Bloom-Richardson grade, histologic features, administration and response to neoadjuvant therapy, adjuvant therapy and recurrence. Genetic ancestry was estimated from a panel of 80 ancestry-informative markers (AIM).
Results: Luminal B breast cancer subtype was the most prevalent in our population (47.5%), followed by luminal A (23.9%), non-basal triple negative (9.3%), basal-like (8.6%), HER2-enriched (8%), and unknown (2.6%). The average of age at diagnosis was 55 and the average tumor size was 4.08 cm. We found statistical significant differences in age at diagnosis, Bloom-Richardson grade, histologic features, adjuvant chemotherapy and recurrence according to intrinsic subtype. Consistent with North American and European observations, basal-like and non-basal triple negative were poorly differentiated tumors and more likely to be diagnosed at younger ages compared to luminal tumors. Patients diagnosed with HER2-enriched, basal and non-basal triple negative breast cancer had the highest African ancestry.
Conclusions: Luminal B tumors, a high risk subset of ER-positive breast cancer, occur with remarkably higher prevalence in Colombian women with breast cancer compared to North American and European populations. Triple-negative subtypes and HER2-enriched tumors appeared to be more frequent among patients with African ancestry, as observed in North American cohorts. Future studies analyzing the molecular profiles of breast cancer in Colombian women will help us understand the molecular basis of this subtype distribution and compare the molecular characteristics of the different intrinsic subtypes in Colombian Hispanic/Latina patients.
Citation Format: Serrano-Gomez SJ, Sanabria MC, Hernández-Suarez GA, Garcia O, Silva C, Romero A, Mejía JC, Fejerman L, Antonia T, Miele L, Zabaleta J. Increased prevalence of luminal B subtype in Colombian women with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-08-09.
Collapse
Affiliation(s)
- SJ Serrano-Gomez
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - MC Sanabria
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - GA Hernández-Suarez
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - O Garcia
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - C Silva
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - A Romero
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - JC Mejía
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - L Fejerman
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - T Antonia
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - L Miele
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| | - J Zabaleta
- Instituto Nacional de Cancerologia, Bogota, Cundinamarca, Colombia; Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia; Stanley S. Scott Cancer Center, New Orleans, LA; UCSF, San Francisco, CA; Moffitt Cancer Center, Tampa, FL; Department of Genetics, New Orleans, LA; Department of Pediatrics, New Orleans, LA
| |
Collapse
|
26
|
Fortini F, Caliceti C, Pannella M, Aquila G, Morelli M, Pannuti A, Miele L, Rizzo P, Ferrari R. Estrogen receptor β is involved in 17β-estradiol-mediated Notch1 activation and angiogenesis enhancement in human endothelial cells. Vascul Pharmacol 2015. [DOI: 10.1016/j.vph.2015.11.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Gatto A, De Gaetano AM, Giuga M, Ciresa M, Siciliani L, Miele L, Riccardi L, Pizzolante F, Rapaccini GL, Gasbarrini A, Giuliante F, Vecchio FM, Pompili M, Bonomo L. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging. ACTA ACUST UNITED AC 2013; 38:736-44. [PMID: 22986351 DOI: 10.1007/s00261-012-9950-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
PURPOSE We evaluated whether the addition of delayed phase imaging (DPI) gadobenate dimeglumine-enhanced MRI to dynamic postcontrast imaging improves the characterization of small hepatocellular carcinoma (HCC) and the differentiation between HCC, high grade dysplastic nodules (HGDN), and low grade dysplastic nodules (LGDN). METHODS Twenty-five cirrhotic patients with 30 nodules (16 HCC, 8 HGDNs, and 6 LGDNs; maximum size of 3 cm) were included in this retrospective study. The diagnostic reference standard was histology. All the patients underwent MRI both prior to and following intravenous administration of gadobenate dimeglumine. The lesions were classified as hypointense, isointense, hyperintense on DPI for qualitative assessment. In the quantitative analysis the relative tumor-liver contrast to noise ratio (CNR) of the lesions on DPI was calculated. RESULTS All HCCs were hypointense on DPI while only 8 (57.1%) of 14 DNs were hypointense and only 1 of 6 (16.6%) LGDNs was hypointense. There was a statistically significant difference in the hypointensity on DPI between HCCs and DNs (p = 0.003) in the qualitative analysis but not in the CNR values while there was a strong statistically significant difference in the hypointensity on DPI in the qualitative (p = 0.00001) and quantitative analysis (p < 0.05) between LGDNs and the group obtained by unifying HGDNs and HCCs. CONCLUSION DPI is helpful in differentiating HCCs and HGDNs from LGDNs. Demonstration of hypointensity on DPI should raise the suspicion of HGDN or hypovascular HCC in the case of nodules with atypical dynamic pattern.
Collapse
Affiliation(s)
- A Gatto
- Department of Bioimaging and Radiological Sciences, Institute of Radiology, Agostino Gemelli Hospital, Catholic University of The Sacred Heart, 8, Largo A. Gemelli, 00168, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 2013; 33:4173-84. [PMID: 24213577 DOI: 10.1038/onc.2013.471] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Revised: 09/11/2013] [Accepted: 09/30/2013] [Indexed: 12/20/2022]
Abstract
The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.
Collapse
Affiliation(s)
- R Ciarapica
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - M De Salvo
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | | | - G Bracaglia
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - L Adesso
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - P P Leoncini
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | | | - Z S Walters
- Sarcoma Molecular Pathology, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
| | - F Verginelli
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - L De Sio
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - R Boldrini
- Department of Pathology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - A Inserra
- Department of Surgery, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - G Bisogno
- Department of Pediatrics, Oncohematology Unit, University of Padova, Padova, Italy
| | - A Rosolen
- Department of Pediatrics, Oncohematology Unit, University of Padova, Padova, Italy
| | - R Alaggio
- Medicine DIMED, Pathology Unit, University of Padova, Padova, Italy
| | - A Ferrari
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Collini
- Anatomic Pathology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Locatelli
- Scientific Directorate, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - S Stifani
- Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
| | - I Screpanti
- Department of Molecular Medicine, Sapienza University, Roma, Italy
| | - S Rutella
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | - Q Yu
- Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
| | - V E Marquez
- Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, CCR, National Cancer Institute, NIH, Frederick, MD, USA
| | - J Shipley
- Sarcoma Molecular Pathology, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
| | - S Valente
- Istituto Pasteur, Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University, Roma, Italy
| | - A Mai
- Istituto Pasteur, Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University, Roma, Italy
| | - L Miele
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - P L Puri
- 1] IRCCS Fondazione Santa Lucia, Roma, Italy [2] Muscle Development and Regeneration Program, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA
| | - F Locatelli
- 1] Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy [2] Dipartimento di Scienze Pediatriche, Università di Pavia, Pavia, Italy
| | - D Palacios
- IRCCS Fondazione Santa Lucia, Roma, Italy
| | - R Rota
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| |
Collapse
|
29
|
Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis 2013; 2:e60. [PMID: 23917222 PMCID: PMC3759125 DOI: 10.1038/oncsis.2013.26] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Revised: 06/14/2013] [Accepted: 06/19/2013] [Indexed: 12/23/2022] Open
Abstract
The Notch pathway is functionally important in breast cancer. Notch-1 has been reported to maintain an estrogen-independent phenotype in estrogen receptor α (ERα)+ breast cancer cells. Notch-4 expression correlates with Ki67. Notch-4 also plays a key role in breast cancer stem-like cells. Estrogen-independent breast cancer cell lines have higher Notch activity than estrogen-dependent lines. Protein kinase Cα (PKCα) overexpression is common in endocrine-resistant breast cancers and promotes tamoxifen (TAM)-resistant growth in breast cancer cell lines. We tested whether PKCα overexpression affects Notch activity and whether Notch signaling contributes to endocrine resistance in PKCα-overexpressing breast cancer cells.Analysis of published microarray data from ERα+ breast carcinomas shows that PKCα expression correlates strongly with Notch-4. Real-time reverse transcription PCR and immunohistochemistry on archival specimens confirmed this finding. In a PKCα-overexpressing, TAM-resistant T47D model, PKCα selectively increases Notch-4, but not Notch-1, expression in vitro and in vivo. This effect is mediated by activator protein-1 (AP-1) occupancy of the Notch-4 promoter. Notch-4 knockdown inhibits estrogen-independent growth of PKCα-overexpressing T47D cells, whereas Notch-4IC expression stimulates it. Gene expression profiling shows that multiple genes and pathways associated with endocrine resistance are induced in Notch-4IC- and PKCα-expressing T47D cells. In PKCα-overexpressing T47D xenografts, an orally active γ-secretase inhibitor at clinically relevant doses significantly decreased estrogen-independent tumor growth, alone and in combination with TAM. In conclusion, PKCα overexpression induces Notch-4 through AP-1. Notch-4 promotes estrogen-independent, TAM-resistant growth and activates multiple pathways connected with endocrine resistance and chemoresistance. Notch inhibitors should be clinically evaluated in PKCα- and Notch-4-overexpressing, endocrine-resistant breast cancers.
Collapse
Affiliation(s)
- J Yun
- Cardinal Bernardin Cancer Center and Department of Pathology, Loyola University Chicago, Maywood, IL, USA
| | - A Pannuti
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - I Espinoza
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - H Zhu
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - C Hicks
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - X Zhu
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - M Caskey
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - P Rizzo
- Cardinal Bernardin Cancer Center and Department of Pathology, Loyola University Chicago, Maywood, IL, USA
| | - G D'Souza
- Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - K Backus
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| | - M F Denning
- Cardinal Bernardin Cancer Center and Department of Pathology, Loyola University Chicago, Maywood, IL, USA
| | - J Coon
- Department of Pathology, Rush University Chicago, Chicago, IL, USA
| | - M Sun
- Department of Cancer Biology, University of Chicago, Chicago, IL, USA
| | - E H Bresnick
- Department of Cell and Regenerative Biology, University of Wisconsin, Madison, WI, USA
| | - C Osipo
- Cardinal Bernardin Cancer Center and Department of Pathology, Loyola University Chicago, Maywood, IL, USA
| | - J Wu
- Department of Cell and Regenerative Biology, University of Wisconsin, Madison, WI, USA
| | - P R Strack
- Merck Research Laboratories, Boston, MA, USA
| | - D A Tonetti
- Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, USA
| | - L Miele
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA
| |
Collapse
|
30
|
Miele L, Marrone G, Cefalo C, D'Achille S, Rapaccini GL, Gasbarrini A, Grieco A. Potential use of liver function breath tests in the clinical practice. Eur Rev Med Pharmacol Sci 2013; 17 Suppl 2:82-89. [PMID: 24443073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Assessment of hepatic functional reserve in acute and chronic liver disease is a discriminating factor for prognostic and therapeutic reasons. For this reason dynamic liver function tests have been developed. AIM To review the breath method with stable carbon isotopes in hepatological setting. MATERIALS AND METHODS We conducted a literature review to analyze the experimental evidence about the diagnostic potential of breath tests of liver function. RESULTS Liver breath tests are able to discriminate between healthy subjects and patients with liver cirrhosis. The use for the assessment of liver fibrosis seems to be still burdened with less capability to discriminate between intermediate stages. CONCLUSIONS Liver breath test are a promising tool for the evaluation of hepatic functional reserve but the use of such methods in clinical practice is limited to specialized or research centers. Most extensive studies are necessary to facilitate the spread of these methods in clinical practice.
Collapse
Affiliation(s)
- L Miele
- Institute of Internal Medicine, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
31
|
Gu JW, King J, Makey KL, Chinchar E, Gibson J, Miele L. Abstract P4-06-04: Gamma-secretase inhibitors suppress the activation of NFκB and the expression of TNFα, IL-6 and IL-8 in triple negative breast cancer cells. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammation mediators, such as NF-kappa B (NFκB) and tumor necrosis factor alpha (TNFα), play major role in breast cancer pathogenesis, progression, and relapse. Triple negative breast cancer (TNBC) is a heterogeneous group of aggressive breast cancers and often has a poor outcome, in which Notch pathways are highly activated. However, role of crosstalk between Notch and inflammation mediators in TNBC progression and recurrence is poorly understood. The present study determines: 1) whether NFκB is highly activated in TNBC cells such as MDA-MB-231 (claudin-low-like) and MDA-MB-468 (basal-like), compared to ER-positive cells (MCF-7); 2) whether TNFα, IL-6 and IL-8 are highly expressed in TNBC cells, compared to MCF-7 cells; 3) whether Notch inhibition by gamma-secretase inhibitors (GSIs) significantly decrease NFκB activation and the expression of TNFα, IL-6 and IL-8 in TNBC cells; 4) whether GSI inhibits TNBC cell migration.
Material and Methods: MDA-MB-231, MDA-MB-468, MCF-7 cells were cultured using RPMI 1640 media with 10% FBS. The cells were exposed to GSIs such as DAPT and RO4929097 for 18 hours. Nuclear NFκB activation was determined by using the TransAM NFκB p65 kit (Active Motif). The expressions of TNFα, IL-6, IL-8, and IFNγ were determined by the ELISA kits (R&D Systems). Migration was determined using BD BioCoat Matrigel Invasion Chamber (BD Bioscience Discovery Labware, Sedford, MA).
Results: Nuclear NFκB p65 activations (A450) were 0.292±0.015, 0.222±0.005, and 0.132±0.004 in cultured MDA-MB-231, MDA-MB-468, and MCF-7 cells, respectively, in which the negative control was 0.125±0.008 and the difference between the groups were significant (P < 0.01, n=6). TNFα protein level was 266±14 pg/mg in MDA-MB-468 cells, but it was not detected in MCF-7 and MDA-MB-231 cells. IL-8 protein levels were 42.8±3, 30.3±2, and 0.23±0.01 ng/mg in MDA-MB-468, MDA-MB-231, and MCF-7 cells, respectively (P < 0.01 between groups, n=6). IL-6 protein levels were 17.1±0.9, 13.9±0.7, and 0.11±0.02 ng/mg in MDA-MB-468, MDA-MB-231, and MCF-7 cells, respectively (P < 0.01 between groups, n=6). IFNγ was not detected in these three cell lines. DAPT (20 µmol/L) or RO4929097 (10 µmol/L) caused 47.7% or 30.6% reduction in NFκB activation, 34.6% or 32.1% reduction in TNFα expression, and 22.2% or 16.4% reduction in IL-8 expression in MDA-MB-468 cells, compared to DMSO group (P < 0.01, n=6). GSIs had no effect on IL-6 expression. DAPT (20 µmol/L) significantly reduced migration of MDA-MB-468 cells by 23%, compared to DMSO group (P < 0.01, n=6).
Discussion: The novel findings are 1) NFκB is highly activated in TNBC cells, compared to ER-positive cells, which is associated with significantly increased the expression of inflammation mediators such as IL-6 and IL-8 in TNBC cells and TNFα in MDA-MB-468; and 2) Notch inhibition by GSIs significantly decrease NFκB activation and the expression of TNFα, and IL-8 in TNBC cells. These results support the hypothesis that the crosstalk between Notch and NFκB lead to activation of inflammation mediators such as TNFα and IL 8, which contribute to TNBC progression and recurrence.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-06-04.
Collapse
Affiliation(s)
- J-W Gu
- University of Mississippi Medical Center, Jackson, MS
| | - J King
- University of Mississippi Medical Center, Jackson, MS
| | - KL Makey
- University of Mississippi Medical Center, Jackson, MS
| | - E Chinchar
- University of Mississippi Medical Center, Jackson, MS
| | - J Gibson
- University of Mississippi Medical Center, Jackson, MS
| | - L Miele
- University of Mississippi Medical Center, Jackson, MS
| |
Collapse
|
32
|
Espinoza I, Caskey M, Baker RC, Miele L. Abstract P6-04-22: Regulation of Notch localization by endocrine therapy in Estrogen Receptor positive breast cancer cells: Clinical implications for endocrine resistance. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-04-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Estrogen receptors occur in about two-thirds of breast tumors and endocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. However, after an initial response to hormonal therapy, most tumors develop resistance leading to disease progression. Central mechanisms thought to be involved in this process include: 1) alterations in tumor cell physiology causing insensitivity to drug-induced apoptosis or induction of drug-detoxifying mechanisms; 2) expression of energy-dependent transporters that eject anti-cancer drugs from cells and 3) the emergence of cancer stem-like cell clones that are estrogen-independent and/or antiestrogen resistant. We and others have shown that Notch signaling mediates survival signals in ER+ breast cancer cells; induces expression of drug transporter ABCG2 (BCRP), activates ERα in the absence of estrogen and mediates survival of breast cancer stem-like cells. Previously, we demonstrated a crosstalk between ERα and Notch signaling whereby estrogen inhibits Notch activation and estrogen withdrawal or tamoxifen re-activate Notch, a possible mechanism of resistance. The mechanism of these effects has remained elusive.
Methods: we used sub-cellular fractionation and immunofluorescence staining to investigate the total expression and cellular distribution of Notch signaling components in MCF-7 cells treated with 17-β-estradiol, or estrogen-free medium.
Results: Our data shows that in cells treated with estrogen-free medium, Notch1 is located in the Lipid Rafts (LR) in the plasma membrane, along with Notch signaling components such as presenilin 1 (the catalytic subunit of γ-secretase), ADAM10 and Notch negative regulator NUMB. There is published evidence that γ-secretase is most active in lipid rafts.17-β-Estradiol modifies the membrane lipid composition and change the localization of Notch and Notch regulators (such as ADAM10, presenilin-1 and NUMB) at the plasma membrane, thereby altering the activation of Notch. These observations are consistent with a model in which the lipid composition of the plasma membrane is a critical factor in regulating the rate of Notch activation. FDA-approved cholesterol lowering drugs affect Notch signaling in ways consistent with this model.
Conclusions: Our findings indicate that endocrine therapy affects Notch signaling at least in part through alterations in membrane composition and lipid raft localization of Notch signaling components.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-04-22.
Collapse
Affiliation(s)
| | - M Caskey
- University of Mississippi, Jackson, MS
| | - RC Baker
- University of Mississippi, Jackson, MS
| | - L Miele
- University of Mississippi, Jackson, MS
| |
Collapse
|
33
|
Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14:433-46. [PMID: 22142056 DOI: 10.1111/j.1463-1326.2011.01543.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIM Aim of this study was to analyse clinical correlates of HbA1c, and of overall, nocturnal, and severe hypoglycaemia, through direct-weighted regressions, as well as the effect of different insulin regimens and insulin analogues, through meta-analysis. METHODS Appropriate methodology (PRISMA statement) was used. Sixty-seven randomized studies, published as full papers were analysed to identify predictors of both HbA1c and hypoglycaemia; studies were included in a meta-analysis to study the effect of different insulin regimens or insulin analogues on HbA1c and hypoglycaemia during the first year of insulin treatment in type 2 diabetes patients. RESULTS Final HbA1c, change of HbA1c, hypoglycaemia, nocturnal hypoglycaemia and severe hypoglycaemia were associated with intensity of treatment. Final HbA1c was higher with basal than with twice-a-day or prandial, and with twice-a-day than with prandial regimen, with opposite figures for hypoglycaemia. Within basal regimens, detemir and glargine were similar to NPH insulin on HbA1c, with less hypoglycaemia and nocturnal hypoglycaemia; within prandial regimens, new analogues were more effective than regular insulin on HbA1c, and induced less hypoglycaemia. The effect of glargine on HbA1c and on hypoglycaemia vanished with increasing number of insulin injections. CONCLUSION Metabolic control and hypoglycaemia are associated with intensity of treatment. Basal regimens have a reduced effect on metabolic control, but are associated with lower frequency of hypoglycaemia. Newer analogues, short- and long-acting, yield better control and less hypoglycaemia than older analogues.
Collapse
Affiliation(s)
- A E Pontiroli
- Cattedra di Medicina Interna e Cattedra di Biometria, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano, and Ospedale San Paolo, Milano, Italy.
| | | | | |
Collapse
|
34
|
Makey K, Patterson SG, Robinson J, Loftin M, Waddell DE, Miele L, Chinchar E, Huang M, Smith AD, Weber M, Gu JW. P3-08-03: Exercise Increases Soluble Vascular Endothelial Growth Factor Receptor-1 (sFlt-1) in the Circulation of Adult Women. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-08-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Physical inactivity increases the risk of several different cancers, including breast cancer. Soluble fms-like tyrosine kinase-1 (sFlt-1) is an extra-cellular Ig-like domain of the VEGF receptor-1 that is released into the extracellular space and circulation where it inhibits the activities of VEGF. Over-expression of sFlt-1 has been shown to inhibit ovarian tumor growth in gene therapy experiments. The present study tests the hypothesis that exercise can increase sFlt-1 in the circulation of adult women.
Material and Methods: 63 African American and Caucasian adult woman volunteers aged 18–44 were enrolled into a prospective exercise study. All the participants walked on a treadmill for 30 minutes at a moderate intensity (40-60% heart rate reserve), and oxygen consumption (VO2) was quantified by utilizing a metabolic cart. Blood samples were collected before and immediately after exercise. The exercise test was conducted between the first and seventh day of the participant's menstrual cycle. The plasma concentrations of sFlt-1, unbound VEGF, and endostatin were measured using ELISA kits from R and D Systems.
Results: Plasma levels of sFlt-1 were 67.8±3.7 pg/ml immediately after exercise (30 minutes), significantly higher than basal levels of 54.5±3.3 pg/ml before exercise (P<0.01; n=63). The % increase in sFlt-1 levels before and after exercise in adult women was 54%. There was no significant difference in the % increase of sFlt-1 levels between African American and Caucasian groups (P=0.5334). There was no significant difference in plasma levels of endostatin before (92.4±4.4 ng/ml) and immediately after (93.8±4.4 ng/ml; P=0.8216) exercise. The basal plasma levels of unbound VEGF (21.5±4.3 pg/ml) ware similar to the plasma levels of VEGF (22.5±4.6 pg/ml; P=0.8652) immediately after exercise.
Discussion: We previously reported that plasma levels of sFlt-1 significantly increased 30 minutes after exercise in adult men, in which plasma levels of unbound-VEGF significantly decreased and plasma levels of endostatin significantly increased 2 hours after exercise. Until now, there has been no data on whether exercise increases plasma sFlt-1 levels in women. Our study is the first to show that exercise in adult women significantly increases plasma levels of sFlt-1. VEGF pathways have both autocrine and paracrine effects for promoting breast cancer progression. Previous studies have demonstrated that sFlt-1 inhibits the activities of VEGF and suppresses ovarian tumor growth in mice. Exercise-induced plasma levels of sFlt-1 could be an important clinical biomarker to explore the mechanisms of exercise training in reducing breast cancer progression. The sFtl-1 is produced in the microvascular and macrovascular endothelial cells that exist throughout the skeletal muscle tissues. It is therefore plausible that release of sFlt-1 from the skeletal muscles into the circulation might be due to exercise-dependent reductions in oxygen tension in the skeletal muscle. In future studies, we will determine whether sFlt-1 can be released directly from the exercised muscle.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-08-03.
Collapse
Affiliation(s)
- K Makey
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - SG Patterson
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - J Robinson
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - M Loftin
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - DE Waddell
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - L Miele
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - E Chinchar
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - M Huang
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - AD Smith
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - M Weber
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| | - J-W Gu
- 1University of Mississippi Medical Center, Jackson, MS; University of Mississippi, Oxford, MS
| |
Collapse
|
35
|
Makey KL, Tucker KB, Chinchar E, Miele L, Pei I, Thomas EY, Gu JW. P3-17-07: EGCG, a Green Tea Antioxidant Suppresses Breast Tumor Angiogenesis and Growth Via Inhibiting the Activation of HIF-1a and NFκB, and VEGF Expression. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-17-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Cancer cells are under greater oxidative stress than normal cells. Limited studies have showed that epigallocatechin-3-gallate (EGCG), a green tea antioxidant can afford protection against a variety of cancer types. The role of EGCG in breast cancer therapy is poorly understood. The present study tests the hypothesis that EGCG as an antioxidant can inhibit the activation of HIF-1α and NFκB, and VEGF expression, thereby suppressing tumor angiogenesis and breast cancer progression.
Material and Methods: 16 eight-wk-old female mice (C57BL/6J) were inoculated with 10^6 E0771 (mouse breast cancer) cells in the left fourth mammary gland fat pad. 8 mice received EGCG at 50–100 mg/kg/d in drinking water for 4 weeks. 8 control mice received drinking water only. Tumor size was monitored using dial calipers. At the end of the experiment, blood samples, tumors, heart and limb muscles were collected for measuring VEGF expression using ELISA and capillary density (CD) using CD31 immunochemistry. Cultured E0771 cells were used for determining the direct effects of EGCG on proliferation (3H-thymidine incorporation), migration (Matrigel assay), VEGF expression (ELISA), the activation of HIF-1α and NFκB (motif binding assays, Active Motif). MCF-7 and MDA-MB-231 cells were also used for 3H-thymidine incorporation.
Results: Oral EGCG treatment significantly reduced tumor weight over the control (0.37±0.15 vs. 1.16±0.30 g; P<0.01), tumor CD (109±20 vs. 156±12 capillary #/mm^2; P<0.01), tumor VEGF expression (45.72±1.4 vs. 59.03±3.8 pg/mg; P<0.01), respectively. EGCG treatment reduced plasma VEGF levels over the control mice (26.48±3.76 vs. 40.79±3.5 pg/ml; P<0.01). However, there were no differences in the body weight and heart weight between EGCG and the control groups. EGCG did not inhibit angiogenesis and VEGF expression in the heart and skeletal muscle of mice, compared to the control. EGCG at 50 mmol/L significantly inhibited the activation of HIF-1α (0.11±0.02 vs. 0.24±0.02; P<0.01) and NFκB (1.15±0.21 vs. 1.61±0.32; P<0.01) as well as VEGF expression (1752±49 vs. 2254±91 pg/mg; P<0.01) in cultured E0771 cells, compared to the control, respectively. EGCG caused a dose-related inhibition on the proliferation and migration in cultured E0771 cells. EGCG also caused a dose-related inhibition on the proliferation in cultured MCF-7 and MDA-MB-231 cells.
Discussion: These findings support the hypothesis that EGCG, a green tea antioxidant, directly targets both tumor cells and tumor vasculature, thereby inhibiting tumor growth, proliferation, migration, and angiogenesis of breast cancer, which is mediated by the inhibition of HIF-1α and NFκB activation as well as VEGF expression. Interestingly, oral EGCG treatment has no effects on the body weight, heart weight, angiogenesis and VEGF expression in the heart and skeletal muscle of mice. This work will have important implications for translating EGCG therapy to human breast cancer treatment and prevention.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-17-07.
Collapse
Affiliation(s)
- KL Makey
- 1University of Mississippi Medical Center, Jackson, MS
| | - KB Tucker
- 1University of Mississippi Medical Center, Jackson, MS
| | - E Chinchar
- 1University of Mississippi Medical Center, Jackson, MS
| | - L Miele
- 1University of Mississippi Medical Center, Jackson, MS
| | - I Pei
- 1University of Mississippi Medical Center, Jackson, MS
| | - EY Thomas
- 1University of Mississippi Medical Center, Jackson, MS
| | - J-W Gu
- 1University of Mississippi Medical Center, Jackson, MS
| |
Collapse
|
36
|
Gu JW, Young E, Patterson SG, Makey KL, Huang M, Tucker KB, Chinchar E, Miele L. P4-03-02: High Fat Diet-Induced Postmenopausal Obesity Promotes Tumor Angiogenesis and Breast Cancer Progression in Age-Relevant Ovariectomized Mice. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-03-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Obese postmenopausal women have 50% higher risk of breast cancer than non-obese women. The mechanisms of postmenopausal obesity-induced breast cancer are poorly understood due to lack of the established animal model that mimics postmenopausal obesity related to breast cancer progression.
Material and Methods: Using age-relevant C57BL/6 mice, this study determined whether postmenopausal obesity increases VEGF expression, tumor angiogenesis, and breast tumor growth. Ovariectomy (OVX) was performed in 12 sixty week-old female mice (life span is about 140 weeks), then followed by a low-fat (5%, LF, n=6) or a high-fat (60%, HF, n=6) diet for 12 weeks. In the 8th wk of the dietary program, 10^6 E0771 (mouse breast cancer) cells were injected in the left fourth mammary gland. Tumor size was monitored using dial calipers for 4 wk. Body weights were monitored weekly. At the end of the experiment, blood samples, visceral fat, and tumors were collected for measuring VEGF expression using ELISA and intratumoral microvessel density (IMD) using CD31 immunochemistry.
Results: Body weight was significantly increased in OVX/HF mice, compared to OVX/LF group (55.3±1.7 vs. 41.5±1.5 g; P<0.01). There was a two-fold increase in the ratio of visceral fat/BW in OVX/HF mice, compared to those in OVX/LF group (0.062±0.005 vs. 0.032±0.003; P<0.01). Postmenopausal obesity significantly increased breast tumor weight over the control (4.62±0.63 vs. 1.98±0.27 g; P<0.01) and IMD (173±3.7 vs. 139±4.3 IM#/mm^2; P<0.01). Tumor VEGF levels were higher in OVX/HF mice, compared to OVX/LF group (73.3±3.8 vs. 49.5±4.3 pg/mg protein; P<0.01). Plasma VEGF levels (69±7.1 vs. 48±3.5 pg/ml) and visceral fat VEGF levels (424.4±39.5 vs. 208.5±22.4 pg/mg protein) were significantly increased in OVX/HF mice, compared to OVX/LF group, respectively (n=6; P<0.01). Interestingly, adipose tissue primary culture showed that subcutaneous fat released more VEGF, compared to visceral fat (6.77±1.14 vs. 0.94±0.16 pg/mg tissue; n=6; P<0.01). The abdominal subcutaneous fat expressed more VEGF proteins than visceral fat in OVX/HF mice (692±72 vs. 431±44 pg/mg protein; n=6; P<0.01). There was a strong positive linear correlation between increased breast tumor weight and visceral fat weight in OVX mice (R2=0.7379; N=12; P<0.01). However, there was no significant difference in heart, or kidney weight/body weight ratio between postmenopausal obesity (OVX/HF) mice and the control mice (OVX/LF).
Discussion: Our observations indicate that ovariectomy plus a high fat diet with the inoculation of E0771 (mouse ER+ breast cancer) cells in female wild type >60 week old mice can mimic human obesity-induced postmenopausal breast cancer. The increased tumor angiogenesis in postmenopausal obese mice was correlated with increased breast tumor growth, adipose tissue mass, and adipokines such as VEGF. These findings support the hypothesis that postmenopausal obesity promotes tumor angiogenesis and breast cancer progression, possibly through increased adipose tissue mass and adipokines such as VEGF that could systemically and locally affect breast cancer progression.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-03-02.
Collapse
Affiliation(s)
- J-W Gu
- 1University of Mississippi Medical Center, Jackson, MS
| | - E Young
- 1University of Mississippi Medical Center, Jackson, MS
| | - SG Patterson
- 1University of Mississippi Medical Center, Jackson, MS
| | - KL Makey
- 1University of Mississippi Medical Center, Jackson, MS
| | - M Huang
- 1University of Mississippi Medical Center, Jackson, MS
| | - KB Tucker
- 1University of Mississippi Medical Center, Jackson, MS
| | - E Chinchar
- 1University of Mississippi Medical Center, Jackson, MS
| | - L Miele
- 1University of Mississippi Medical Center, Jackson, MS
| |
Collapse
|
37
|
Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C, De Sio L, Cortese G, Locatelli M, Dang TP, Carlesso N, Miele L, Stifani S, Limon I, Locatelli F, Rota R. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ 2011; 19:871-81. [PMID: 22117196 PMCID: PMC3321627 DOI: 10.1038/cdd.2011.171] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Rhabdomyosarcoma (RMS) is a paediatric soft-tissue sarcoma arising from skeletal muscle precursors coexpressing markers of proliferation and differentiation. Inducers of myogenic differentiation suppress RMS tumourigenic phenotype. The Notch target gene HES1 is upregulated in RMS and prevents tumour cell differentiation in a Notch-dependent manner. However, Notch receptors regulating this phenomenon are unknown. In agreement with data in RMS primary tumours, we show here that the Notch3 receptor is overexpressed in RMS cell lines versus normal myoblasts. Notch3-targeted downregulation in RMS cells induces hyper-phosphorylation of p38 and Akt essential for myogenesis, resulting in the differentiation of tumour cells into multinucleated myotubes expressing Myosin Heavy Chain. These phenomena are associated to a marked decrease in HES1 expression, an increase in p21Cip1 level and the accumulation of RMS cells in the G1 phase. HES1-forced overexpression in RMS cells reverses, at least in part, the pro-differentiative effects of Notch3 downregulation. Notch3 depletion also reduces the tumourigenic potential of RMS cells both in vitro and in vivo. These results indicate that downregulation of Notch3 is sufficient to force RMS cells into completing a correct full myogenic program providing evidence that it contributes, partially through HES1 sustained expression, to their malignant phenotype. Moreover, they suggest Notch3 as a novel potential target in human RMS.
Collapse
Affiliation(s)
- L Raimondi
- Department of Oncohematology, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011; 13:1008-19. [PMID: 21645195 DOI: 10.1111/j.1463-1326.2011.01433.x] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
AIM This systematic review and meta-analysis was to evaluate the body weight increase and its clinical correlates, through direct weighted regressions, as well as the effect of different insulin regimens and insulin analogues, through meta-analysis. METHODS Appropriate methodology according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was adhered to. Forty-six randomized studies, published as full papers, reporting the effect of insulin treatment on change in body weight were identified, and used to identify predictors of weight change; studies were included in a meta-analysis to study the effect of different insulin regimens or insulin analogues on weight change. RESULTS Intensity of treatment [aim of study (fasting blood glucose, mg/dl), dose of insulin, final HbA1c, change of HbA1c and frequency of hypoglycaemia] was significantly associated with body weight increase, with small differences between basal versus twice-a-day and prandial regimen. At meta-analysis, body weight increase was lower with basal regimen than with twice-a-day regimen and than with a prandial regimen. Within all regimens, body weight increase was lower with detemir than with NPH, with no difference between glargine and NPH; only two studies directly compared detemir and glargine, indicating lower weight gain with the former insulin. Within twice-a-day regimens and within prandial regimens, comparison was between newer analogues and older drugs, with no significant difference in body weight increase. CONCLUSION Body weight increase during the first year of insulin treatment is associated with the intensity of treatment; body weight increase also depends on the insulin regimen applied.
Collapse
Affiliation(s)
- A E Pontiroli
- Cattedra di Medicina Interna e Cattedra di Biometria, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano and Ospedale San Paolo, Milano, Italy.
| | | | | |
Collapse
|
39
|
Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 2011; 105:796-806. [PMID: 21847123 PMCID: PMC3171020 DOI: 10.1038/bjc.2011.321] [Citation(s) in RCA: 110] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2011] [Revised: 07/12/2011] [Accepted: 07/18/2011] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both trastuzumab-sensitive and trastuzumab-resistant, ErbB-2-positive, BT474 breast tumours in vivo. We also studied if the combination therapy of lapatinib plus GSI can induce tumour regression of ErbB-2-positive breast cancer. METHODS We generated orthotopic breast tumour xenografts from trastuzumab- or lapatinib-sensitive and trastuzumab-resistant BT474 cells. We investigated the antitumour activities of two distinct GSIs, LY 411 575 and MRK-003, in vivo. RESULTS Our findings showed that combining trastuzumab plus a GSI completely prevented (MRK-003 GSI) or significantly reduced (LY 411 575 GSI) breast tumour recurrence post-trastuzumab treatment in sensitive tumours. Moreover, combining lapatinib plus MRK-003 GSI showed significant reduction of tumour growth. Furthermore, a GSI partially reversed trastuzumab resistance in resistant tumours. CONCLUSION Our data suggest that a combined inhibition of Notch and ErbB-2 signalling pathways could decrease recurrence rates for ErbB-2-positive breast tumours and may be beneficial in the treatment of recurrent trastuzumab-resistant disease.
Collapse
MESH Headings
- Amyloid Precursor Protein Secretases/antagonists & inhibitors
- Amyloid Precursor Protein Secretases/therapeutic use
- Animals
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Breast Neoplasms/prevention & control
- Cell Line, Tumor
- Cyclic S-Oxides/pharmacology
- Drug Resistance, Neoplasm
- Female
- Gene Targeting
- Genes, erbB
- Genes, erbB-2
- Humans
- Lapatinib
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Quinazolines/administration & dosage
- Receptor, ErbB-2/metabolism
- Receptors, Notch/antagonists & inhibitors
- Receptors, Notch/genetics
- Recurrence
- Signal Transduction/drug effects
- Thiadiazoles/pharmacology
- Trastuzumab
Collapse
Affiliation(s)
- K Pandya
- Molecular Biology Program, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
| | - K Meeke
- Oncology Institute, Stritch School of Medicine at Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
| | - A G Clementz
- Molecular and Cellular Biochemistry Program, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
| | - A Rogowski
- Molecular Biology Program, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
| | - J Roberts
- Oncology Institute, Stritch School of Medicine at Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
| | - L Miele
- University of Mississippi Cancer Institute, 350 Woodrow Wilson Drive, Suite 600, Jackson, MS 39213, USA
| | - K S Albain
- Department of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
| | - C Osipo
- Molecular Biology Program, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
- Oncology Institute, Stritch School of Medicine at Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
- Molecular and Cellular Biochemistry Program, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA
- Department of Pathology, 2160 South First Avenue, Maywood, IL 60153, USA
- Department of Microbiology and Immunology, 2160 South First Avenue, Maywood, IL 60153, USA
| |
Collapse
|
40
|
Rota R, Raimondi L, Ciarapica R, Verginelli F, Gueguen M, Boldrini R, De Sio L, Inserra A, Locatelli M, Dang T, Miele L, Stifani S, Limon I, Locatelli F. Effect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Gibney B, Lee G, Houdek J, Miele L, Lin M, Chamoto K, Konerding M, Tsuda A, Mentzer S. Pulmonary Mechanics Suggest Mechanical Forces Trigger Neoalveolarization In A Murine Model Of Compensatory Lung Growth. J Surg Res 2011. [DOI: 10.1016/j.jss.2010.11.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Albain KS, Czerlanis C, Rajan P, Zlobin A, Godellas C, Bova D, Lo SS, Robinson P, Sarker S, Gaynor ER, Cooper R, Aranha G, Czaplicki K, Busby B, Rizzo P, Chisamore M, Demuth T, Blackman S, Watters J, Stiff P, Fuqua SAW, Miele L. Abstract PD05-12: Combination of Notch Inhibitor MK-0752 and Endocrine Therapy for Early Stage ERα + Breast Cancer in a Presurgical Window Pilot Study. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd05-12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast tumor initiating cells (TIC) use Notch receptors/ligands with other pathways for self renewal, resulting in tumor proliferation and progression. We showed that Notch inhibition with gamma secretase inhibitors (GSI) potentiates the effects of tamoxifen (tam) in xenografts (Rizzo et al. Cancer Res 2008). It is unknown whether GSIs plus endocrine therapy result in modulation of Notch and other proliferation markers in human breast cancer. Our objective was to add short exposure of the GSI MK-0752 to ongoing tam or letrozole (letr) during the presurgical window to determine 1) feasibility, 2) safety/tolerance, and 3) impact on biomarkers. We report the initial cohort of this pilot study (ClinTrials. gov NCT00756717).
Methods: Patients (pts) with early stage ERα + breast cancer were treated with 25 days of tam or letr. On day 15 MK-0752 was added to endocrine therapy (350 mg orally 3 days on, 4 days off, 3 days on), with definitive surgery day 25. Formalin fixed, paraffin embedded biopsies were obtained at baseline, day 14 and final surgery, with histologic confirmation of tumor content >50% and RNA extraction by standard methods. Q-PCR was done for Notch1, Notch3, Notch4, Deltex, Jagged1, c-myc, HEY1, HEY2, HES1, PS2, C-Myc, Cyclin A2, NOXA (pro-apoptotic protein), Ki67, Dicer-1, RPL13 (internal control). Ct averages for 3 replicates were used and mRNA levels were calculated by the 2ΔΔCt method. Baseline gene expression levels were used as comparators for days 14 and 25 levels in each pt. The first cohort of 10 pts was analyzed to determine if enough signals were present to justify expanding the cohort at this dose to 20 pts and possibly test a second cohort on an alternate MK-0752 dose/schedule. Results: The initial cohort of 10 pts completed all therapy (4 tam, 6 letr), all biopsies and definitive surgery on schedule. One other pt withdrew prior to starting MK-0752 due to hypertension. Toxicity was minimal: grade 1 periorbital edema/cough, nausea, and axillary paresthesias in 1 pt each; grade 1 facial rash, 2 pts; and grade 2 fatigue, 1 pt. There was no diarrhea or surgical complications. Significant changes occurred in molecular marker levels after MK-0752 plus tam/letr (day 25) vs. end of tam/letr alone (day 14) as follows: Ki67 mRNA decreased in 9/10 pts; Notch4 decreased, 10/10; NOXA increased, 6/10; and Notch1 decreased, 6/10. Other markers showed inter-individual variations and will be presented, along with results of the global gene expression profiling (in progress). Conclusions: The addition of a short exposure of the GSI MK-0752 to ongoing endocrine therapy was feasible, safe, and well tolerated in pts with ERα + early breast cancer prior to definitive surgery. It results in anti-proliferative and pro-apoptotic effects at the molecular level. Notch4, which plays a key role in breast TIC, was the most consistent molecular marker of response in this setting. This suggests a potential anti-TIC effect of this combination and a role in overcoming endocrine resistance. Accrual to the expanded cohort is underway. If findings are confirmed, the second study with alternate MK-0752 dose/schedule may commence. Funding: Swim Across America, Inc. (clinical trial costs); Merck (drug supply, profiling)
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD05-12.
Collapse
Affiliation(s)
- KS Albain
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - C Czerlanis
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - P Rajan
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - A Zlobin
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - C Godellas
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - D Bova
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - SS Lo
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - P Robinson
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - S Sarker
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - ER Gaynor
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - R Cooper
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - G Aranha
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - K Czaplicki
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - B Busby
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - P Rizzo
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - M Chisamore
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - T Demuth
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - S Blackman
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - J Watters
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - P Stiff
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - SAW Fuqua
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| | - L. Miele
- Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, IL; Merck Oncology, North Wales, PA; Baylor Breast Center, Houston, TX; University of Mississippi Cancer Institute, Jackson, MS
| |
Collapse
|
43
|
Filipovic A, Green A, Shao D, Yague E, Pannuti A, Yao K, Feng G, Lin S, Miele L, Coombes C. Abstract P5-06-04: Nicastrin Reveals Gamma-Secretase Independent Function in Breast Cancer Cells and Can Be Targeted by a Blocking Monoclonal Antibody To Reduce Breast Cancer Cell Proliferation and Invasion. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Nicastrin (NCT) is a structural and functional part of the gamma-secretase (GS) enzyme, implicated in tumorigenesis and resistance to treatment in multiple cancer types. However, its mechanism(s) of action and biological functions are poorly understood. We investigated functional and biological effects of inhibiting NCT in breast cancer (BC)cells by means of gene silencing and blocking antibodies, as well as the prognostic value of NCT expression in BC tissue. METHODS: NCT siRNA (Dahrmacon) was used at 40nM. A polyclonal antibody (pcAb) against NCT extracellular domain was developed at Biogenes (GE), and anti-NCT monoclonal antibodies (mAbs) at Genovac (GE). We tested the Abs for their ability to recognize endogenous NCT in BC cells by FACS and Western blot. Best Abs were tested in vitro, using a transwell cell invasion assay and proliferation assay. Anti-NCT Ab (Sigma, N1660) was used for immunohistochemistry (IHC) staining of BC tissues (n = 1050). Cases were scored as NCT negative (0), 1+, 2+ or 3+. Kaplan Meier analysis was used to investigate impact of NCT expression on survival. Illumina (Agilent) oligonucleotide arrays were used to investigate NCT siRNA effects on gene expression in BC cells. Both PcAb and mAbs recognized endogenous NCT in BC cells. In vitro, blocking NCT in MDA-MB231 BC cells with the PcAb, reduced cell proliferation in a dose dependent manner; by 50% and 70% at concentrations of 50μg/ml and 100μg/ml, respectively. mAbs reduced proliferation by 50% (clones 2H6 and 10C5) and 70% clone 10C11, (P<0.01). In transwell cell invasion assay, anti-NCT pcAb induced a dose dependent reduction of invasion, by 35% at the 5μg/ml, peaking at > 60% reduction at 50μg/ml (P<0.001). mAbs reduced cell invasion by 40-50% (clone 10C5 and 10C11) and by >65% (clone 2H6) (P<001). IHC data showed that NCT was highly expressed (2+, 3+) in 47.5% of BC tissues. High NCT expression correlated with worse overall survival (OS) in ERnegative patients (p=0.05). To elucidate the effects of NCT loss, compared to those induced by GSIs or silencing Notch receptors, we examined cDNA from MDA231 treated independently with NCT, Notch1, Notch2, Notch4 siRNAs and GSI MK-003, on Illumina expression arrays. Thirteen of the 18 genes maximally affected by GSI were similarly affected by NCT siRNA. NCT knockdown also affected 1745 other genes that by large were not affected by GSI or Notch knockdowns. This suggests that NCT has GS-and Notch-independent cellular functions and may have different biological properties as a therapeutic target than GS. Among NCT siRNA affected genes, some are tumor suppressors: CST4 increased 8 fold; pro-invasive genes like GNG11 decreased 4 fold; cell adhesion genes: CTGF increased 4.5 fold etc.
CONCLUSIONS: NCT is overexpressed in 47.5% of BC cases where it infers adverse OS in the ER-vecohort of patients. Anti-NCT mAbs recognize endogenous NCT in BC cells and reduce BC cell proliferation and invasion. Silencing NCT in invasive BC cells induces extensive gene expression changes that only partially overlap with those caused by GSIs or Notch siRNAs. We conclude that NCT has GS-independent functions in BC cells and that an anti-NCT mAb may be a promising therapeutic approach for invasive BC.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-06-04.
Collapse
Affiliation(s)
- A Filipovic
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - A Green
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - D Shao
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - E Yague
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - A Pannuti
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - K Yao
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - G Feng
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - S Lin
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - L Miele
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| | - C. Coombes
- Imperial College London, London, United Kingdom; Univeristy of Nottingham, United Kingdom; University of Mississippi Medical Center, Jackson; University of Mississippi Cancer Institute; Northshore University of Chicago; Northwestern University
| |
Collapse
|
44
|
Biolato M, Basso M, Cassano A, Cefalo C, Miele L, Pompili M, Rapaccini GL, Gasbarrini G, Barone C, Grieco A. Liver functional reserve and survival after sunitinib therapy in cirrhotic patients with advanced hepatocellular carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, Gasbarrini G, Landolfi R, Grieco A. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 2010; 14:356-362. [PMID: 20496548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUND AND OBJECTIVES To provide an overview on the loco-regional therapy performed by transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), either as sole, either as neoadjuvant to surgery or bridge therapy to orthotopic liver transplantation (OLT). EVIDENCE AND INFORMATION SOURCES The current review is based on an analysis of the current literature and the caseload experience of the Authors on this topic. STATE OF THE ART Chemoembolization combines de-arterialization of the tumor and selective delivery of chemotherapeutic agents into tumor's feeding vessels during angiography. Tumor ischemia raises the drug concentration compared to infusion alone and extends the retention of the chemotherapeutic drug. As locoregional therapy, TACE allows a complete local tumor control of 25-35% and permits an increase of survival in patients with intermediate HCC according to Barcelona-Clinic Liver Cancer (BCLC) classification. Excellent results were also achieved by combined therapies, such as with percutaneous ethanol injection or radiofrequency ablation, as neoadjuvant therapy prior to liver resection and in some circumstances as a bridging tool before liver transplantation. PERSPECTIVES Drug eluting beads are microspheres that can be loaded with doxorubicin and induce toxic and ischemic necrosis with the same device; that allows an increase of drug selectively exposed to tumor cells and simultaneously a reduction of systemic toxicity. Tumor embolization induces a neoangiogenic reaction with a significant growth of adiacent satellites, so the association with sorafenib has a strong rationale for a combined therapy and is currently under investigation. CONCLUSIONS Today TACE is the standard of care for treatment of intermediate hepatocellular carcinoma. To get the best performance it should be tailored according to the individual patient's condition.
Collapse
Affiliation(s)
- M Biolato
- Institute of Internal Medicine, School of Medical, Catholic University of the Sacred Heart, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Vero V, Racco S, Biolato M, Pompili M, Gasbarrini G, Miele L, Grieco A. [The treatment of hepatocellular carcinoma: an update]. Minerva Med 2009; 100:173-193. [PMID: 19571783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Hepatocellular carcinoma (HCC) is the third most frequent cause of death from cancer with an increasing incidence in the world. Hepatic cirrhosis is the main risk factor for the development of this tumor, present in more than 80% of cases. The prognosis of this tumor is still poor and appears to be strictly related to liver residual function and tumor extension. A regular surveillance program was defined to increase early detection of tumor in cirrhotic patients when curative treatment could be applied. Liver transplantation and liver resection offer a high rate of positive response when applied in a early stage of the disease; locoregional therapies are effective, palliative options for patients with unresectable HCC: transarterial chemoembolisation being the only with a proven positive impact on survival. Several prognostic systems are proposed in the last years to stratify patients in different risk groups and to identify those who could achieve the best survival benefit from different therapeutic strategies: the Okuda system, the Cancer of the Liver Italian Program and the Barcelona Clínic Liver Cancer are the most widely used, but there is no consensus to which is the best in predicting outcome most accurately.
Collapse
Affiliation(s)
- V Vero
- Istituto di Medicina Interna, Università Cattolica del Sacro Cuore, Ospedale Gemelli, Roma, Italia
| | | | | | | | | | | | | |
Collapse
|
47
|
Gasbarrini G, Miele L, Malandrino N, Grieco A, Addolorato G, Gasbarrini A, Cammarota G, Bonvicini F. Celiac Disease in the 21st Century: Issues of Under-and Over-Diagnosis. Int J Immunopathol Pharmacol 2009; 22:1-7. [DOI: 10.1177/039463200902200101] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Until the 1960s celiac disease (CD) or sprue was considered a pediatric disease that was rarely diagnosed in adulthood. Thanks to greater awareness of the disease and the availability of improved diagnostic tools (above all, sophisticated endoscopic techniques and the development of reliable serological markers), the prevalence of CD in Western countries has been increasing steadily, and it is now recognized as a common disorder, even in adults. However, many cases of this disease still go undiagnosed, especially among the elderly and in patients with atypical clinical presentations (which are by no means uncommon). On the other hand, the frequency of unfounded diagnoses of CD is also on the rise. This reflects a tendency toward exclusively symptomatic diagnosis as well as the growing use of invalidated tests for CD (e.g., the cytotoxic test, the sublingual or subcutaneous provocation/neutralization test, etc.). As a result, public healthcare spending is being increased in several countries (Italy included) by the growing number of prescriptions for gluten-free diets. This editorial discusses the problems of under- and over-diagnosis of CD and provides an algorithm for management of suspected cases designed to minimize both problems with particular importance to morphologic aspects of small bowel (also in electron microscopy), in basal conditions or in gluten-free diets.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - F. Bonvicini
- Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy
| |
Collapse
|
48
|
Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, Kast WM, Stone PJB, Santos L, Loredo A, Lendahl U, Sonenshein G, Osborne B, Qin JZ, Pannuti A, Nickoloff BJ, Miele L. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene 2008; 27:5833-44. [PMID: 18560356 DOI: 10.1038/onc.2008.190] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2007] [Revised: 04/30/2008] [Accepted: 05/12/2008] [Indexed: 02/03/2023]
Abstract
Notch-1 inhibits apoptosis in some transformed cells through incompletely understood mechanisms. Notch-1 can increase nuclear factor-kappa B (NF-kappaB) activity through a variety of mechanisms. Overexpression of cleaved Notch-1 in T-cell acute lymphoblastic leukemia cells activates NF-kappaB via interaction with the I kappa B kinase (IKK) signalosome. Concomitant activation of the Notch and NF-kappaB pathways has been described in a large series of cervical cancer specimens. Here, we show that wild-type, spontaneously expressed Notch-1 stimulates NF-kappaB activity in CaSki cervical cancer cells by associating with the IKK signalosome through IKKalpha. A significant fraction of tumor necrosis factor (TNF)-alpha-stimulated IkappaB kinase activity in CaSki cells is Notch-1-dependent. In addition, Notch-1 is found in the nucleus in association with IKKalpha at IKKalpha-stimulated promoters and is required for association of IKKalpha with these promoters under basal and TNF-alpha-stimulated conditions. Notch-1-IKKalpha complexes are found in normal human keratinocytes as well, suggesting that IKK regulation is a physiological function of Notch-1. Both Notch-1 and IKKalpha knockdown sensitize CaSki cells to cisplatin-induced apoptosis to equivalent extents. Our data indicate that Notch-1 regulates NF-kappaB in cervical cancer cells at least in part via cytoplasmic and nuclear IKK-mediated pathways.
Collapse
Affiliation(s)
- L L Song
- Breast Cancer Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
|
50
|
Abstract
Accumulating preclinical and clinical evidence supports a pro-oncogenic function for Notch signaling in several solid tumors, particularly but not exclusively in breast cancer. Notch inhibitory agents, such as gamma-secretase inhibitors, are being investigated as candidate cancer therapeutic agents. Interest in therapeutic modulation of the Notch pathway has been increased by recent reports, indicating that its role is important in controlling the fate of putative 'breast cancer stem cells'. However, as is the case for most targeted therapies, successful targeting of Notch signaling in cancer will require a considerable refinement of our understanding of the regulation of this pathway and its effects in both normal and cancer cells. Notch signaling has bidirectional 'cross talk' interaction with multiple other pathways that include candidate therapeutic targets. Understanding these interactions will greatly increase our ability to design rational combination regimens. To determine which patients are most likely to benefit from treatment with Notch inhibitors, it will be necessary to develop molecular tests to accurately measure pathway activity in specific tumors. Finally, mechanism-based toxicities will have to be addressed by a careful choice of therapeutic agents, combinations and regimens. This article summarizes the current state of the field, and briefly describes opportunities and challenges for Notch-targeted therapies in oncology.
Collapse
Affiliation(s)
- P Rizzo
- Breast Cancer Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, Chicago, IL 60163, USA
| | | | | | | | | | | |
Collapse
|